Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
OKYO 
OKYO Pharma Ltd ADR (OKYO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/31/2025: OKYO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $10
1 Year Target Price $10
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -56.15% | Avg. Invested days 20 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/31/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 103.05M USD | Price to earnings Ratio - | 1Y Target Price 10 |
Price to earnings Ratio - | 1Y Target Price 10 | ||
Volume (30-day avg) 1 | Beta -4.46 | 52 Weeks Range 0.90 - 3.35 | Updated Date 11/2/2025 |
52 Weeks Range 0.90 - 3.35 | Updated Date 11/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.12 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -169.87% | Return on Equity (TTM) -2968.51% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 73483747 | Price to Sales(TTM) - |
Enterprise Value 73483747 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -4.29 | Shares Outstanding 37610676 | Shares Floating 25081808 |
Shares Outstanding 37610676 | Shares Floating 25081808 | ||
Percent Insiders 38.44 | Percent Institutions 7.37 |
Upturn AI SWOT
OKYO Pharma Ltd ADR
Company Overview
History and Background
OKYO Pharma Ltd. is a biopharmaceutical company focusing on developing therapies for ocular diseases. Founded to address unmet needs in eye care, it leverages advanced technologies to develop innovative treatments.
Core Business Areas
- Pharmaceutical Development: Focuses on the development of novel therapies for dry eye disease, uveitis, and other inflammatory eye conditions.
- Drug Delivery Systems: Involves utilizing advanced drug delivery technologies to improve the efficacy and safety of ocular treatments.
Leadership and Structure
The company is led by a team of experienced executives and scientists in the pharmaceutical industry. Organizational structure includes departments for research and development, clinical trials, and commercialization.
Top Products and Market Share
Key Offerings
- OK-101: A lipid-conjugated chemerin peptide designed to treat dry eye disease by targeting ocular inflammation and corneal nerve health. Phase 2 trials are ongoing. Competitors include Novartis' Xiidra, AbbVie's Restasis, and Sun Pharma's Cequa. Market share is currently N/A as it is in clinical trials.
- OK-201: A clinical candidate being developed for treating inflammatory dry eye disease and uveitis. Market share is currently N/A as it is in pre-clinical development.
Market Dynamics
Industry Overview
The ophthalmic pharmaceutical industry is characterized by strong growth due to an aging population and increasing prevalence of eye diseases. The market is competitive, with both large pharmaceutical companies and smaller biotech firms vying for market share.
Positioning
OKYO Pharma Ltd ADR aims to differentiate itself through innovative drug delivery systems and targeted therapies for unmet medical needs in eye care. Their competitive advantage lies in novel peptide-based therapeutics.
Total Addressable Market (TAM)
The global dry eye disease market is projected to reach billions of USD. OKYO Pharma Ltd ADR is positioned to capture a portion of this TAM with its targeted therapies.
Upturn SWOT Analysis
Strengths
- Novel drug candidates targeting unmet needs
- Experienced management team
- Proprietary drug delivery technology
- Strong IP portfolio
Weaknesses
- Limited financial resources compared to larger competitors
- Reliance on successful clinical trial outcomes
- Limited commercialization experience
Opportunities
- Growing market for ophthalmic therapies
- Potential for strategic partnerships or acquisitions
- Expanding into new therapeutic areas within ophthalmology
- Favorable regulatory environment
Threats
- Competition from established pharmaceutical companies
- Failure to achieve positive clinical trial results
- Regulatory hurdles
- Patent expiration
Competitors and Market Share
Key Competitors
- SNY
- ABBV
- NVS
- LLY
Competitive Landscape
OKYO Pharma Ltd ADR is a smaller player in a competitive market. It relies on innovative therapies to compete with larger, established companies. OKYO focuses on novel peptide technology with advantages on treating inflammation and improving corneal health.
Growth Trajectory and Initiatives
Historical Growth: Growth is characterized by advancing drug candidates through clinical trials rather than revenue generation.
Future Projections: Future growth depends on successful clinical trial outcomes and potential regulatory approvals. Analyst estimates vary significantly.
Recent Initiatives: Recent initiatives include advancing OK-101 and OK-201 through clinical trials and seeking strategic partnerships.
Summary
OKYO Pharma is a clinical-stage biopharmaceutical company with potential in the ophthalmic space, particularly with its OK-101 candidate. Its strength lies in novel peptide technology. However, its success depends on positive clinical trial results and securing funding, while facing competition from established companies. Monitoring clinical progress and financial stability is critical.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market data is dynamic and subject to change. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About OKYO Pharma Ltd ADR
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2022-05-17 | CEO & Executive Director Dr. Gary S. Jacob Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 4 | Website https://okyopharma.com |
Full time employees 4 | Website https://okyopharma.com | ||
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase II clinical trials for the treatment of dry eye disease; in Phase II clinical trial to treat neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis. The company is also developing OK-201 for the treatment acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.